Fig. 1

The process through which EBV-dependent post-transplant lymphoproliferative diseases emerge after the transplantation of allogeneic SCs. Latent membrane protein 1/2 (LMP 1 and LMP 2), which is altered in EBV infections and activated by primary B cells, is one of the oncogenes encoded by EBV. An important contributor to the rise in post-transplant lymphoproliferative diseases is host immunosuppression brought on by the conditioning regimen, the use of immunosuppressive agents, and development benefits from EBV-infected cells brought on by post-transplant lymphoproliferative disorders (PTLD). Continuous immune system activity, persistent inflammation, and a rise in GVHD and PTLD are all brought on by conditioning regimens. ** Damage-Associated Molecular patterns (DAMPs), Epstein—Barr virus Nuclear Antigen (EBNA)